0001209191-18-017693.txt : 20180307 0001209191-18-017693.hdr.sgml : 20180307 20180307161340 ACCESSION NUMBER: 0001209191-18-017693 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180305 FILED AS OF DATE: 20180307 DATE AS OF CHANGE: 20180307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bozigian Haig P. CENTRAL INDEX KEY: 0001423837 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 18673519 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-05 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001423837 Bozigian Haig P. 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Development Officer Common Stock 2018-03-05 4 M 0 61474 5.76 A 197471 D Common Stock 2018-03-05 4 S 0 61474 90.00 D 135997 D Common Stock 2018-03-05 4 M 0 14399 43.24 A 150396 D Common Stock 2018-03-05 4 S 0 14399 90.00 D 135997 D Non-Qualified Stock Option 5.76 2018-03-05 4 M 0 61474 5.76 A 2021-08-25 Common Stock 61474 18243 D Non-Qualified Stock Option 43.24 2018-03-05 4 M 0 14399 43.24 A 2027-02-06 Common Stock 14399 59460 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011. Option granted February 06, 2017 and vested monthly over four years. /s/ Darin Lippoldt, Attorney-in-Fact 2018-03-07